Uncertainty around pharma tariffs on and pricing policies under the Trump has much of the sector guessing what will happen ...

Sanofi said it will invest at least $20 billion in the US through 2030, joining other pharmaceutical companies boosting their ...

German healthcare and materials group Merck KGaA has dropped a surcharge on life sciences sector orders within China ...

European governments are examining whether U.S. President Donald Trump can force them to pay more for prescription medicines, ...

Toward the end of his first Administration, Trump signed a similar Executive Order aimed at lowering the prices of some drugs ...

Merck filed for approval of gefapixant in March 2021 on the strength of a pair of phase 3 trials – COUGH-1 and COUGH-2 – which found that the drug reduced 24-hour cough frequency by 18% and 15 ...

As history has made clear, presidential price controls require an act of Congress, and there is no possible way that is going ...

Instead, said Kaitin, drugs hit the US market first because the sponsors choose to submit them there first. The advantage of the US is almost wholly down to its lack of price controls, says Kaitin.

While the concept of HCP portals is a good one, the perception and impact has sometimes been underwhelming. Many organisations report low engagement amongst HCPs, and HCPs themselves talk of ...